Brief: HCW Biologics Says Substantial Doubt Exists Regarding Ability To Continue As Going Concern For At Least 12 Months
18/08/2025 20:17
Aug 18 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS REPORTS SECOND QUARTER 2025 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS HCW BIOLOGICS, INC Q2 BASIC EPS USD -6.79 HCW BIOLOGICS- AS OF JUNE 30, BELIEVES SUBSTANTIAL DOUBT EXISTS REGARDING ABILITY TO CONTINUE AS GOING CONCERN FOR AT LEAST 12 MONTHS Source text: ID:nGNX3FTvp5 Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock
Brief: HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen
Brief: HCW Biologics Prices Private Placement Of 2.8 Mln Units At $1.405 Per Unit
NASDAQ RESUMED AT 09:59 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM